Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Increased Hypermethylation of Glutathione S-Transferase P1, DNA-Binding Protein Inhibitor, Death Associated Protein Kinase and Paired Box Protein-5 Genes in Triple-Negative Breast Cancer Saudi Females

  • Hafez, Mohamed M. (Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University) ;
  • Al-Shabanah, Othman A. (Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University) ;
  • Al-Rejaie, Salim S. (Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University) ;
  • Al-Harbi, Naif O. (Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University) ;
  • Hassan, Zeinab K. (Zoology Department, College of Science, King Saud University) ;
  • Alsheikh, Abdulmalik (Department of Pathology, College of Medicine, King Saud University) ;
  • Theyab, Abdurrahman I. Al (Oncology Division, Department of Internal Medicine, College of Medicine, King Saud University) ;
  • Aldelemy, Meshan L. (King Abdullah International Medical Research Center) ;
  • Sayed-Ahmed, Mohamed M. (Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University)
  • Published : 2015.02.25
Download PDF
⟨ Previous Next ⟩

Abstract

Triple negative breast cancer (TNBC) is an aggressive subtype of breast cancer (BC) with higher metastatic rate and both local and systemic recurrence compared to non-TNBC. The generation of reactive oxygen species (ROS) secondary to oxidative stress is associated with DNA damage, chromosomal degradation and alterations of both hypermethylation and hypomethylation of DNA. This study concerns differential methylation of promoter regions in specific groups of genes in TNBC and non-TNBC Saudi females in an effort to understand whether epigenetic events might be involved in breast carcinogenesis, and whether they might be used as markers for Saudi BCs. Methylation of glutathione S-transferase P1 (GSTP1), T-cadherin (CDH13), Paired box protein 5 (PAX5), death associated protein kinase (DAPK), twist-related protein (TWIST), DNA-binding protein inhibitor (ID4), High In Normal-1 (HIN-1), cyclin-dependent kinase inhibitor 2A (p16), cyclin D2 and retinoic acid receptor-${\beta}$ ($RAR{\beta}1$) genes was analyzed by methylation specific polymerase chain reaction (MSP) in 200 archival formalin-fixed paraffin embedded BC tissues divided into 3 groups; benign breast tissues (20), TNBC (80) and non-TNBC (100). The relationships between methylation status, and clinical and pathological characteristics of patients and tumors were assessed. Higher frequencies of GSTP1, ID4, TWIST, DAPK, PAX5 and HIN-1 hypermethylation were found in TNBC than in non-TNBC. Hypermethylation of GSTP1, CDH13, ID4, DAPK, HIN-1 and PAX5 increased with tumor grade increasing. Other statistically significant correlations were identified with studied genes. Data from this study suggest that increased hypermethylation of GSTP1, ID4, TWIST, DAPK, PAX5 and HIN-1 genes in TNBC than in non-TNBC can act as useful biomarker for BCs in the Saudi population. The higher frequency of specific hypermethylated genes paralleling tumor grade, size and lymph node involvement suggests contributions to breast cancer initiation and progression.

Keywords

References

  1. Aboserea M, Abdelgawad Mwafik W (2011). Early detection of breast cancer among females at fakous district, sharqia governorate, egypt. Life Science J, 8, 196-203.
  2. Al Tamimi DM, Shawarby MA, Ahmed A, et al (2010). Protein expression profile and prevalence pattern of the molecular classes of breast cancer--a Saudi population based study. BMC Cancer, 10, 223. https://doi.org/10.1186/1471-2407-10-223
  3. Asemi Z, Jazayeri S, Najafi M, et al (2012). Effect of daily consumption of probiotic yogurt on oxidative stress in pregnant women: a randomized controlled clinical trial. Ann Nutr Metab, 60, 62-8. https://doi.org/10.1159/000335468
  4. Askari M, Sobti RC, Nikbakht M, et al (2013). Promoter hypermethylation of tumour suppressor genes (p14/ARF and p16/INK4a): case-control study in North Indian population. Mol Biol Rep, 40, 4921-8. https://doi.org/10.1007/s11033-013-2592-5
  5. Bae YK, Shim YR, Choi JH, et al (2005). Gene promoter hypermethylation in tumors and plasma of breast cancer patients. Cancer Res Treat, 37, 233-40. https://doi.org/10.4143/crt.2005.37.4.233
  6. Cho NY, Kim JH, Moon KC, et al (2009). Genomic hypomethylation and CpG island hypermethylation in prostatic intraepithelial neoplasm. Virchows Arch, 454, 17-23. https://doi.org/10.1007/s00428-008-0706-6
  7. Cho YH, Shen J, Gammon MD, et al (2012). Prognostic significance of gene-specific promoter hypermethylation in breast cancer patients. Breast Cancer Res Treat, 131, 197-205. https://doi.org/10.1007/s10549-011-1712-y
  8. Dai D, Dong XH, Cheng ST, et al (2014). Aberrant promoter methylation of HIN-1 gene may contribute to the pathogenesis of breast cancer: a meta-analysis. Tumour Biol, 35, 8209-16. https://doi.org/10.1007/s13277-014-2055-1
  9. Danbara M, Kameyama K, Higashihara M, et al (2002). DNA methylation dominates transcriptional silencing of Pax5 in terminally differentiated B cell lines. Mol Immunol, 38, 1161-6. https://doi.org/10.1016/S0161-5890(02)00003-2
  10. Das PMSingal R (2004). DNA methylation and cancer. J Clin Oncol, 22, 4632-42. https://doi.org/10.1200/JCO.2004.07.151
  11. Demokan S, Chuang A, Suoglu Y, et al (2012). Promoter methylation and loss of p16(INK4a) gene expression in head and neck cancer. Head Neck, 34, 1470-5. https://doi.org/10.1002/hed.21949
  12. Ellmann L, Joshi MB, Resink TJ, et al (2012). BRN2 is a transcriptional repressor of CDH13 (T-cadherin) in melanoma cells. Lab Invest, 92, 1788-800. https://doi.org/10.1038/labinvest.2012.140
  13. Escobar-Cabrera Je BSLaGAG (2013). The role of transcription factor twist in cancer cells. J Genet Syndr Gene Ther 4, 1-7.
  14. Evron E, Umbricht CB, Korz D, et al (2001). Loss of cyclin D2 expression in the majority of breast cancers is associated with promoter hypermethylation. Cancer Res, 61, 2782-7.
  15. Feng W, Orlandi R, Zhao N, et al (2010). Tumor suppressor genes are frequently methylated in lymph node metastases of breast cancers. BMC Cancer, 10, 378. https://doi.org/10.1186/1471-2407-10-378
  16. Feng W, Shen L, Wen S, et al (2007). Correlation between CpG methylation profiles and hormone receptor status in breast cancers. Breast Cancer Res, 9, 57. https://doi.org/10.1186/bcr1762
  17. Flamini MI, Gauna GV, Sottile ML, et al (2014). Retinoic acid reduces migration of human breast cancer cells: role of retinoic acid receptor beta. J Cell Mol Med, 18, 1113-3. https://doi.org/10.1111/jcmm.12256
  18. Gheibi A, Kazemi M, Baradaran A, et al (2012). Study of promoter methylation pattern of 14-3-3 sigma gene in normal and cancerous tissue of breast: a potential biomarker for detection of breast cancer in patients. Adv Biomed Res, 1, 80.
  19. Gypas F, Bei ES, Zervakis M, et al (2011). A disease annotation study of gene signatures in a breast cancer microarray dataset. Conf Proc IEEE Eng Med Biol Soc, 2011, 5551-4.
  20. Hamamori Y, Sartorelli V, Ogryzko V, et al (1999). Regulation of histone acetyltransferases p300 and PCAF by the bHLH protein twist and adenoviral oncoprotein E1A. Cell, 96, 405-13. https://doi.org/10.1016/S0092-8674(00)80553-X
  21. Henrique R, Costa VL, Cerveira N, et al (2006). Hypermethylation of Cyclin D2 is associated with loss of mRNA expression and tumor development in prostate cancer. J Mol Med (Berl). 84, 911-8. https://doi.org/10.1007/s00109-006-0099-4
  22. Jentzmik F, Krause H, Reichelt U, et al (2012). GSTP1 CpG island hypermethylation for DNA-based detection of occult tumor cells in surgical margins after radical prostatectomy. World J Urol, 30, 541-6. https://doi.org/10.1007/s00345-011-0764-2
  23. Jha AK, Nikbakht M, Jain V, et al (2012). p16(INK4a) and p15(INK4b) gene promoter methylation in cervical cancer patients. Oncol Lett, 3, 1331-5.
  24. Jung EJ, Kim IS, Lee EY, et al (2013). Comparison of methylation profiling in cancerous and their corresponding normal tissues from korean patients with breast cancer. Ann Lab Med, 33, 431-40. https://doi.org/10.3343/alm.2013.33.6.431
  25. Kaczmarczyk G, Lewandowski R, Trautsolt W, et al (2012). Cytological examination of pleural cavity lavage accompanied by the study of gene promoter hypermethylation of p16 and O6-methylguanine-DNA-methyltransferase genes in diagnostics of non-small cell lung cancer metastatic changes into pleura. Contemp Oncol (Pozn). 16, 322-7.
  26. Khor GH, Froemming GR, Zain RB, et al (2013). DNA methylation profiling revealed promoter hypermethylationinduced silencing of p16, DDAH2 and DUSP1 in primary oral squamous cell carcinoma. Int J Med Sci, 10, 1727-39. https://doi.org/10.7150/ijms.6884
  27. Kornegoor R, Moelans CB, Verschuur-Maes AH, et al (2012). Promoter hypermethylation in male breast cancer: analysis by multiplex ligation-dependent probe amplification. Breast Cancer Res, 14, 101. https://doi.org/10.1186/bcr3056
  28. Krop IE, Sgroi D, Porter DA, et al (2001). HIN-1, a putative cytokine highly expressed in normal but not cancerous mammary epithelial cells. Proc Natl Acad Sci USA, 98, 9796-801. https://doi.org/10.1073/pnas.171138398
  29. Lee JS, Fackler MJ, Lee JH, et al (2010). Basal-like breast cancer displays distinct patterns of promoter methylation. Cancer Biol Ther, 9, 1017-24. https://doi.org/10.4161/cbt.9.12.11804
  30. Lehmann U, Celikkaya G, Hasemeier B, et al (2002). Promoter hypermethylation of the death-associated protein kinase gene in breast cancer is associated with the invasive lobular subtype. Cancer Res, 62, 6634-8.
  31. Liu X, Nugoli M, Laferriere J, et al (2011). Stromal retinoic acid receptor beta promotes mammary gland tumorigenesis. Proc Natl Acad Sci U S A, 108, 774-9. https://doi.org/10.1073/pnas.1011845108
  32. Mehrotra J, Vali M, McVeigh M, et al (2004). Very high frequency of hypermethylated genes in breast cancer metastasis to the bone, brain, and lung. Clin Cancer Res, 10, 3104-9. https://doi.org/10.1158/1078-0432.CCR-03-0118
  33. Mishra DK, Chen Z, Wu Y, et al (2010). Global methylation pattern of genes in androgen-sensitive and androgenindependent prostate cancer cells. Mol Cancer Ther, 9, 33-45.
  34. Moelans CB, Verschuur-Maes AHvan Diest PJ (2011). Frequent promoter hypermethylation of BRCA2, CDH13, MSH6, PAX5, PAX6 and WT1 in ductal carcinoma in situ and invasive breast cancer. J Pathol, 225, 222-31. https://doi.org/10.1002/path.2930
  35. Narayan G, Arias-Pulido H, Koul S, et al (2003). Frequent promoter methylation of CDH1, DAPK, RARB, and HIC1 genes in carcinoma of cervix uteri: its relationship to clinical outcome. Mol Cancer, 2, 24. https://doi.org/10.1186/1476-4598-2-24
  36. Noetzel E, Veeck J, Niederacher D, et al (2008). Promoter methylation-associated loss of ID4 expression is a marker of tumour recurrence in human breast cancer. BMC Cancer, 8, 154. https://doi.org/10.1186/1471-2407-8-154
  37. O'Brien P, Morin P, Jr., Ouellette RJ, et al (2011). The Pax-5 gene: a pluripotent regulator of B-cell differentiation and cancer disease. Cancer Res, 71, 7345-50. https://doi.org/10.1158/0008-5472.CAN-11-1874
  38. Palmisano WA, Crume KP, Grimes MJ, et al (2003). Aberrant promoter methylation of the transcription factor genes PAX5 alpha and beta in human cancers. Cancer Res, 63, 4620-5.
  39. Panayiotidis MI (2014). Cancer epigenetics as biomarkers of clinical significance. Cancer Lett, 342, 168-9. https://doi.org/10.1016/j.canlet.2013.10.027
  40. Park SY, Kwon HJ, Lee HE, et al (2011). Promoter CpG island hypermethylation during breast cancer progression. Virchows Arch, 458, 73-84. https://doi.org/10.1007/s00428-010-1013-6
  41. Peurala E, Koivunen P, Haapasaari KM, et al (2013). The prognostic significance and value of cyclin D1, CDK4 and p16 in human breast cancer. Breast Cancer Res, 15, 5.
  42. Radpour R, Barekati Z, Kohler C, et al (2011). Hypermethylation of tumor suppressor genes involved in critical regulatory pathways for developing a blood-based test in breast cancer. PLoS One, 6, 16080. https://doi.org/10.1371/journal.pone.0016080
  43. Raffo P, Emionite L, Colucci L, et al (2000). Retinoid receptors: pathways of proliferation inhibition and apoptosis induction in breast cancer cell lines. Anticancer Res, 20, 1535-43.
  44. Sakuma M, Akahira J, Ito K, et al (2007). Promoter methylation status of the Cyclin D2 gene is associated with poor prognosis in human epithelial ovarian cancer. Cancer Sci, 98, 380-6. https://doi.org/10.1111/j.1349-7006.2007.00394.x
  45. Sanchez-Cespedes M, Esteller M, Wu L, et al (2000). Gene promoter hypermethylation in tumors and serum of head and neck cancer patients. Cancer Res, 60, 892-5.
  46. Sturgeon SR, Balasubramanian R, Schairer C, et al (2012). Detection of promoter methylation of tumor suppressor genes in serum DNA of breast cancer cases and benign breast disease controls. Epigenetics, 7, 1258-67. https://doi.org/10.4161/epi.22220
  47. Suijkerbuijk SJ, van Osch MH, Bos FL, et al (2010). Molecular causes for BUBR1 dysfunction in the human cancer predisposition syndrome mosaic variegated aneuploidy. Cancer Res, 70, 4891-900. https://doi.org/10.1158/0008-5472.CAN-09-4319
  48. Sung CO, Lee KW, Han S, et al (2011). Twist1 is up-regulated in gastric cancer-associated fibroblasts with poor clinical outcomes. Am J Pathol, 179, 1827-38. https://doi.org/10.1016/j.ajpath.2011.06.032
  49. Tan J, Gu Y, Zhang X, et al (2012). Hypermethylation of CpG islands is more prevalent than hypomethylation across the entire genome in breast carcinogenesis. Clin Exp Med, 13, 1-9
  50. Tuononen K, Tynninen O, Sarhadi VK, et al (2012). The hypermethylation of the O6-methylguanine-DNA methyltransferase gene promoter in gliomas--correlation with array comparative genome hybridization results and IDH1 mutation. Genes Chromosomes Cancer, 51, 20-29. https://doi.org/10.1002/gcc.20927
  51. Umetani N, Mori T, Koyanagi K, et al (2005). Aberrant hypermethylation of ID4 gene promoter region increases risk of lymph node metastasis in T1 breast cancer. Oncogene, 24, 4721-7. https://doi.org/10.1038/sj.onc.1208538
  52. Vincent TLGatenby RA (2008). An evolutionary model for initiation, promotion, and progression in carcinogenesis. Int J Oncol, 32, 729-37.
  53. Wang YJ, He L, Yuan M, et al (2014). Epigenetic changes of TIMP-3, GSTP-1 and 14-3-3 sigma genes as indication of status of chronic inflammation and cancer. Int J Biol Markers, 29, 208-14 https://doi.org/10.5301/jbm.5000104
  54. Wani HA, Beigh MA, Amin S, et al (2013). Methylation profile of promoter region of p16 gene in colorectal cancer patients of Kashmir valley. J Biol Regul Homeost Agents, 27, 297-307.
  55. Weiwei F, Lanlan S, Sijin W, et al (2007). Correlation between CpG methylation profiles and hormone receptor status in breast cancers. Breast Cancer Research, 9, 1-13.
  56. Wu Y, Elshimali Y, Sarkissyan M, et al (2012). Expression of FOXO1 is associated with GATA3 and Annexin-1 and predicts disease-free survival in breast cancer. Am J Cancer Res, 2, 104-15.
  57. Xu J, Shetty PB, Feng W, et al (2012). Methylation of HIN-1, RASSF1A, RIL and CDH13 in breast cancer is associated with clinical characteristics, but only RASSF1A methylation is associated with outcome. BMC Cancer, 12, 243. https://doi.org/10.1186/1471-2407-12-243
  58. Yamamoto N, Nakayama T, Kajita M, et al (2012). Detection of aberrant promoter methylation of GSTP1, RASSF1A, and RARbeta2 in serum DNA of patients with breast cancer by a newly established one-step methylation-specific PCR assay. Breast Cancer Res Treat, 132, 165-73. https://doi.org/10.1007/s10549-011-1575-2
  59. Yuan N, Meng M, Liu C, et al (2014). Clinical characteristics and prognostic analysis of triple-negative breast cancer patients. Mol Clin Oncol, 2, 245-51.
  60. Zhao YF, Shen SP, Jiang JY, et al (2010). Methylation and expression of gene p16INK4a and RB in breast carcinoma. Zhonghua Bing Li Xue Za Zhi, 39, 377-81 (in Chinese).

Cited by

  1. LCN2 Promoter Methylation Status as Novel Predictive Marker for Microvessel Density and Aggressive Tumor Phenotype in Breast Cancer Patients vol.16, pp.12, 2015, https://doi.org/10.7314/APJCP.2015.16.12.4965
  2. A Systematic Analysis of the Relationship of CDH13 Promoter Methylation and Breast Cancer Risk and Prognosis vol.11, pp.5, 2016, https://doi.org/10.1371/journal.pone.0149185
  3. Recent Progress in Triple Negative Breast Cancer Research vol.17, pp.4, 2016, https://doi.org/10.7314/APJCP.2016.17.4.1595
  4. Assessment of the functional impact of germline BRCA1/2 variants located in non-coding regions in families with breast and/or ovarian cancer predisposition vol.168, pp.2, 2018, https://doi.org/10.1007/s10549-017-4602-0